欧洲六种关键抗生素耐药病原体所致血流感染频率的系统综述:用于研究优先级排序和新疗法发现
该系统综述检索多个数据库和监测平台,纳入271项研究和52个监测系统,评估欧洲六种关键耐药菌所致血流感染的频率指标。最高耐药百分比为碳青霉烯耐药鲍曼不动杆菌(中東欧66%)和碳青霉烯耐药肺炎克雷伯菌(南欧62.8%);社区感染耐药百分比低于医疗相关感染,儿童低于成人。纳入数据质量中等,作者认为现有频率指标不足以指导抗生素管理和研发策略,亟需改进数据收集和标准化。
要点
- 碳青霉烯耐药鲍曼不动杆菌耐药百分比最高,中東欧达66%;碳青霉烯耐药肺炎克雷伯菌南欧达62.8%。
- 社区感染耐药百分比低于医疗相关感染,儿童低于成人。
- 作者认为病原体特异性耐药频率指标不足以指导抗生素管理和研发策略。
核心结论
- 血流感染中病原体特异性抗菌药物耐药频率指标不足以指导抗生素管理和研究开发策略,亟需改进数据收集和频率指标标准化。
研究设计与样本
- 系统综述,检索PubMed、Web of Science、Embase数据库和ECRAID-Base流行病学网络平台,纳入评估六种关键细菌所致血流感染耐药百分比、患病率或发病密度的研究和监测系统,使用改良Joanna Briggs Institute工具评价研究质量,采用随机效应Meta分析合并估计值。
- 共纳入来自32个欧洲国家的271项研究和52个监测系统;45项研究(16%)报告血流感染,包括180项频率指标,最常见为耐药百分比(88项,48.9%);从24个(46%)监测系统中提取309项频率指标,其中278项(89%)为耐药百分比。
主要发现
- 耐甲氧西林金黄色葡萄球菌和耐万古霉素屎肠球菌血流感染的频率指标更多来自南欧和西欧(80%),而碳青霉烯耐药铜绿假单胞菌血流感染更多来自北欧和西欧(88%)。
- 最高耐药百分比为碳青霉烯耐药鲍曼不动杆菌(中東欧66%)和碳青霉烯耐药肺炎克雷伯菌(南欧62.8%)。
- 合并估计显示社区感染耐药百分比低于医疗相关感染,儿童低于成人。
- 研究和监测系统的估计值在欧洲各区域之间大多一致;纳入数据质量中等。
关键数值与推荐
- 碳青霉烯耐药鲍曼不动杆菌耐药百分比中東欧为66%。
- 碳青霉烯耐药肺炎克雷伯菌耐药百分比南欧为62.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入数据质量中等。
- 病原体特异性抗菌药物耐药频率指标不足以指导抗生素管理和研究开发策略。
- 亟需改进数据收集和频率指标标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To prioritize healthcare investments, ranking of infections caused by antibiotic-resistant bacteria should be based on accurate incidence data. OBJECTIVES: We performed a systematic review to estimate frequency measures of antimicrobial resistance for six key bacteria causing bloodstream infections (BSI) in European countries. DATA SOURCES: We searched PubMed, Web of Science, Embase databases, and the ECRAID-Base Epidemiological-Network platform. STUDY ELIGIBILITY CRITERIA: We included studies and surveillance systems assessing resistance-percentage, prevalence, or incidence-density of BSI because of carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli, third-generation cephalosporins-resistant E. coli and K. pneumoniae, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus. METHODS: Reviewers independently assessed published data and evaluated study quality with the modified Joanna Briggs Institute critical appraisal tool. Pooled estimates were determined using random effects meta-analysis. Consistency of data was assessed using random effects meta-regression (Wald test, p > 0.05). RESULTS: We identified 271 studies and 52 surveillance systems from 32 European countries. Forty-five studies (16%) reported on BSI, including 180 frequency measures most commonly as resistance-percentage (88, 48.9%). Among 309 frequency measures extracted from 24 (46%) surveillance systems, 278 (89%) were resistance-percentages. Frequency measures of methicillin-resistant S. aureus and vancomycin-resistant E. faecium BSI were more frequently reported from Southern Europe and Western Europe (80%), whereas carbapenem-resistant P. aeruginosa BSI from Northern Europe and Western Europe (88%). Highest resistance-percentages were detected for carbapenem-resistant A. baumannii (66% in Central Eastern Europe) and carbapenem-resistant K. pneumoniae (62.8% in Southern Europe). Pooled estimates showed lower resistance-percentages in community versus healthcare-associated infections and in children versus adults. Estimates from studies and surveillance systems were mostly consistent among European regions. The included data was of medium quality. DISCUSSION: Pathogen-specific frequency measures of antimicrobial resistance in BSI are insufficient to inform antibiotic stewardship and research and development strategies. Improving data collection and standardization of frequency measures is urgently needed.
引用
- Pezzani MD, Arieti F, Rajendran NB, et al. Frequency of bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research and discovery of new therapies in Europe: a systematic review. Clin Microbiol Infect. 2023. PMID: 38007387. doi:10.1016/j.cmi.2023.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。